132 related articles for article (PubMed ID: 23391551)
1. [Pharmacological and clinical profile of mogamulizumab (POTELIGEO(®) Injection)].
Kobatake C; Mizutani M; Amou M; Yurimoto S
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):100-5. PubMed ID: 23391551
[No Abstract] [Full Text] [Related]
2. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
[No Abstract] [Full Text] [Related]
3. [Companion diagnostics "POTELIGEO TEST IHC/FCM" used with "POTELIGEO" (mogamulizumab) for adult T-cell leukemia-lymphoma (ATL) treatment].
Goami T
Rinsho Byori; 2014 May; 62(5):450-6. PubMed ID: 25051659
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
5. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
6. Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab.
Cook LBM; Demontis MA; Sagawe S; Witkover A; Melamed A; Turpin J; Dillon R; Haddow J; Marks AJ; Bangham CRM; Fields P; Taylor GP; Rowan AG
Haematologica; 2019 Dec; 104(12):e566-e569. PubMed ID: 31004017
[No Abstract] [Full Text] [Related]
7. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
[TBL] [Abstract][Full Text] [Related]
8. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
9. Marketing approval of mogamulizumab: a triumph for glyco-engineering.
Beck A; Reichert JM
MAbs; 2012; 4(4):419-25. PubMed ID: 22699226
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
11. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
12. Ascites Retention during Mogamulizumab Treatment in a Patient with Adult T-cell Leukemia/lymphoma.
Shima T; Kamezaki K; Higashioka K; Takashima S; Yoshimoto G; Kato K; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K
Intern Med; 2016; 55(13):1793-6. PubMed ID: 27374686
[TBL] [Abstract][Full Text] [Related]
13. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
[No Abstract] [Full Text] [Related]
14. [Mogamulizumab for the treatment of ATL and PTCL].
Tsukasaki K
Gan To Kagaku Ryoho; 2015 May; 42(5):553-7. PubMed ID: 26054089
[No Abstract] [Full Text] [Related]
15. Strong effect of mogamulizumab on splenic residual disease of adult T cell leukemia/lymphoma.
Ohgiya D; Machida S; Ichiki A; Amaki J; Aoyama Y; Kawai H; Miyamoto M; Murayama H; Onizuka M; Ando K
Ann Hematol; 2014 Apr; 93(4):719-20. PubMed ID: 23949316
[No Abstract] [Full Text] [Related]
16. No effect of humanized CCR monoclonal antibody (mogamulizumab) on treatment-resistant adult T cell leukemia with meningeal infiltration.
Tsutsumi Y; Shimono J; Miyashita N; Teshima T
Leuk Lymphoma; 2014 Feb; 55(2):457-9. PubMed ID: 23697876
[No Abstract] [Full Text] [Related]
17. Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab.
Tamaki K; Kinjo T; Aoyama H; Tomoyose T; Nakachi S; Hanashiro T; Shimabukuro N; Tedokon I; Morichika K; Nishi Y; Taira N; Fujita J; Yoshimi N; Fukushima T; Masuzaki H
J Infect Chemother; 2015 Nov; 21(11):820-3. PubMed ID: 26231316
[TBL] [Abstract][Full Text] [Related]
18. [Adult T-cell leukemia-lymphoma with severe hepatic damage and fluid retention successfully treated with mogamulizumab].
Shodai A; Inoue H; Kamada Y; Fujino S; Tabuchi T; Arima N; Uchida Y; Hachiman M; Nakamura D; Yoshimitsu M; Ishitsuka K
Rinsho Ketsueki; 2020; 61(6):612-616. PubMed ID: 32624533
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
[TBL] [Abstract][Full Text] [Related]
20. [Long-term remission with mogamulizumab monotherapy in a patient with refractory adult T-cell leukemia-lymphoma].
Nakaya Y; Tsutsumi M; Fuseya H; Horiuchi M; Yoshimura T; Hayashi Y; Kanashima H; Nakao T; Yamane T
Rinsho Ketsueki; 2018; 59(3):326-328. PubMed ID: 29618693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
